Iranian Red Crescent Medical Journal

Published by: Kowsar

Comparison of Serum Levels of Procalcitonin and C-Reactive Protein in Patients with Community Acquired Pneumonia and COPD Exacerbation

Ali Taghizadieh 1 , Hassan Soleimanpour 2 , Farzad Rahmani 3 , * , Kavous Shahsavari Nia 3 and Hossein Khodaverdizadeh 4
Authors Information
1 Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
2 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
3 Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran
4 Student's Research Committee, Tabriz University of Medical Sciences, Tabriz, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: December 01, 2016, 18 (12); e25811
  • Published Online: August 7, 2016
  • Article Type: Research Article
  • Received: December 9, 2014
  • Revised: June 27, 2015
  • Accepted: July 22, 2015
  • DOI: 10.5812/ircmj.25811

To Cite: Taghizadieh A, Soleimanpour H, Rahmani F, Shahsavari Nia K, Khodaverdizadeh H. Comparison of Serum Levels of Procalcitonin and C-Reactive Protein in Patients with Community Acquired Pneumonia and COPD Exacerbation, Iran Red Crescent Med J. 2016 ; 18(12):e25811. doi: 10.5812/ircmj.25811.

Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011; 139(6): 1410-8[DOI][PubMed]
  • 2. Gholamnejad M, Rezaie N. Unusual presentation of chronic eosinophilic pneumonia with "reversed halo sign": a case report. Iran J Radiol. 2014; 11(2): 7891[DOI][PubMed]
  • 3. Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010; 36(3): 601-7[DOI][PubMed]
  • 4. Habibian S, Mehrabi-Tavana A, Ahmadi Z, Izadi M, Jonaidi N, Darakhshanpoure J, et al. Serotype distribution and antibiotics susceptibility pattern of Streptococcus pneumonia in Iran. Iran Red Crescent Med J. 2013; 15(10): 8053[DOI][PubMed]
  • 5. Javadi Nia S, Zarabi V, Noorbakhsh S, Farhadi M, Ghavidel Darestani S. Chlamydophila pneumoniae Infection Assessment in Children With Adenoid Hypertrophy Concomitant With Rhino Sinusitis. Jundishapur J Microbiol. 2014; 7(8)
  • 6. Dalal AA, Patel J, D'Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD Exacerbation Frequency on Costs for a Managed Care Population. J Manag Care Spec Pharm. 2015; 21(7): 575-83[DOI][PubMed]
  • 7. Taghizadieh A, Rahmani F, Soleimanpour H, Aminifazl H. Comparison of End Tidal Carbon Dioxide and Arterial Blood Bicarbonate Levels in Patients With Exacerbation Chronic Obstructive Pulmonary Disease. Thrita. 2015; 4(2)
  • 8. Daniels JM, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010; 138(5): 1108-15[DOI][PubMed]
  • 9. Enguix Armada A, Escobar Conesa R, La Torre AGD, La Torre Prados D, Victoria M. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin. CCLM. 2015; 54(1): 163-8
  • 10. Liu D, Su L, Han G, Yan P, Xie L. Prognostic Value of Procalcitonin in Adult Patients with Sepsis: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10(6): 129450[DOI][PubMed]
  • 11. Que YA, Guessous I, Dupuis-Lozeron E, Alves de Oliveira CR, Ferreira Oliveir C, Graf R, et al. Prognostication of Mortality in Critically Ill Patients With Severe Infections. Chest. 2015; 148(3): 674-82[DOI][PubMed]
  • 12. Angeletti S, Spoto S, Fogolari M, Cortigiani M, Fioravanti M, De Florio L, et al. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections. APMIS. 2015; 123(9): 740-8[DOI][PubMed]
  • 13. Fazili T, Endy T, Javaid W, Maskey M. Role of procalcitonin in guiding antibiotic therapy. Am J Health Syst Pharm. 2012; 69(23): 2057-61[DOI][PubMed]
  • 14. Walsh EE, Swinburne AJ, Becker KL, Nylen ES, Snider RH, Baran A, et al. Can serum procalcitonin levels help interpret indeterminate chest radiographs in patients hospitalized with acute respiratory illness? J Hosp Med. 2013; 8(2): 61-7[DOI][PubMed]
  • 15. Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child. 2001; 84(4): 332-6[PubMed]
  • 16. Berg P, Lindhardt BO. The role of procalcitonin in adult patients with community-acquired pneumonia--a systematic review. Dan Med J. 2012; 59(3): 4357[PubMed]
  • 17. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007; 7: 10[DOI][PubMed]
  • 18. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care. 2010; 14(1): 203[DOI][PubMed]
  • 19. Stolz D, Christ-Crain M, Gencay MM, Bingisser R, Huber PR, Muller B, et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly. 2006; 136(27-28): 434-40[PubMed]
  • 20. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174(1): 84-93[DOI][PubMed]
  • 21. Holm A, Pedersen SS, Nexoe J, Obel N, Nielsen LP, Koldkjaer O. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract. 2007; 57(540): 555-60
  • 22. Masia M, Gutierrez F, Shum C, Padilla S, Navarro JC, Flores E, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest. 2005; 128(4): 2223-9[DOI][PubMed]
  • 23. Falsey AR, Becker KL, Swinburne AJ, Nylen ES, Snider RH, Formica MA, et al. Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. Int J Chron Obstruct Pulmon Dis. 2012; 7: 127-35[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments